Non-invasive UltraShape uses pulsed focused ultrasound energy to remove fat.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Syneron Medical Ltd. (Nasdaq: ELOS) has obtained US Food and Drug Administration (FDA) approval for its non-invasive UltraShape System for fat cell destruction. The product obtained CE Mark in 2005, and is sold in Europe, Canada, and in Asia Pacific countries.
Syneron acquired UltraShape Ltd., which developed the device, in 2012, and subsequently sought to obtain FDA approval for the product. The company sais that the device has been used in over 220, 000 procedures worldwide
“The UltraShape technology is one of the two pillars of our body shaping strategy, ” said Syneron chairman Dr. Shimon Eckhouse. “Our significant investment in the development of non-invasive body shaping products puts us in a unique position to lead the market with UltraShape mechanical fat destruction technology, and with our unique VelaShape III elōs based thermal technology. With these two FDA cleared technologies we have a wide range of body shaping indications including circumferential reduction in various body areas and reduction in cellulite appearance. These two complementary technologies will be key factors for serving our global customer base in the fast growing body shaping market.”